Stock Track | AbCellera Biologics Plummets 11.65% Intraday Amid Concerns Over Continued Losses and Rising R&D Expenses Despite Q1 Beat

Stock Track05-12

AbCellera Biologics' stock plummeted 11.65% during intraday trading on Tuesday, extending significant pre-market losses.

The sharp decline follows the release of the company's first-quarter 2026 financial results. Despite beating analyst expectations for both earnings per share and revenue, investor sentiment turned negative due to concerns over the company's ongoing substantial losses and increased research spending.

The company reported a net loss of $43.2 million for the quarter, and research and development expenses climbed to $46.7 million from $42.5 million a year ago. Additionally, the number of downstream programs led by partners decreased to 40 from 44 at the end of the previous quarter. While the company announced positive interim Phase 1 clinical data for its ABCL635 candidate, investors focused on the challenging financial metrics.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103494780?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103494780","market":"sg","top_or_hot":-1,"title":"Stock Track | AbCellera Biologics Plummets 11.65% Intraday Amid Concerns Over Continued Losses and Rising R&D Expenses Despite Q1 Beat","media":"Stock Track","content":"<p>AbCellera Biologics' stock plummeted 11.65% during intraday trading on Tuesday, extending significant pre-market losses.</p><p>The sharp decline follows the release of the company's first-quarter 2026 financial results. Despite beating analyst expectations for both earnings per share and revenue, investor sentiment turned negative due to concerns over the company's ongoing substantial losses and increased research spending.</p><p>The company reported a net loss of $43.2 million for the quarter, and research and development expenses climbed to $46.7 million from $42.5 million a year ago. Additionally, the number of downstream programs led by partners decreased to 40 from 44 at the end of the previous quarter. While the company announced positive interim Phase 1 clinical data for its ABCL635 candidate, investors focused on the challenging financial metrics.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AbCellera Biologics Plummets 11.65% Intraday Amid Concerns Over Continued Losses and Rising R&D Expenses Despite Q1 Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AbCellera Biologics Plummets 11.65% Intraday Amid Concerns Over Continued Losses and Rising R&D Expenses Despite Q1 Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-12 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AbCellera Biologics' stock plummeted 11.65% during intraday trading on Tuesday, extending significant pre-market losses.</p><p>The sharp decline follows the release of the company's first-quarter 2026 financial results. Despite beating analyst expectations for both earnings per share and revenue, investor sentiment turned negative due to concerns over the company's ongoing substantial losses and increased research spending.</p><p>The company reported a net loss of $43.2 million for the quarter, and research and development expenses climbed to $46.7 million from $42.5 million a year ago. Additionally, the number of downstream programs led by partners decreased to 40 from 44 at the end of the previous quarter. While the company announced positive interim Phase 1 clinical data for its ABCL635 candidate, investors focused on the challenging financial metrics.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABCL","symbol_name":"AbCellera Biologics","start_time":0,"source_url":"","article_id":"1103494780","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103494780","pubTimestamp":1778593550,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AbCellera Biologics' stock plummeted 11.65% during intraday trading on Tuesday, extending significant pre-market losses.The sharp decline follows the release of the company's first-quarter 2026...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABCL":"AbCellera Biologics"},"translate_title":"个股追踪|AbCellera Biologics盘中暴跌11.65%，因担忧Q1业绩持续亏损和研发费用上升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":1},"content_text":"AbCellera Biologics' stock plummeted 11.65% during intraday trading on Tuesday, extending significant pre-market losses.The sharp decline follows the release of the company's first-quarter 2026 financial results. Despite beating analyst expectations for both earnings per share and revenue, investor sentiment turned negative due to concerns over the company's ongoing substantial losses and increased research spending.The company reported a net loss of $43.2 million for the quarter, and research and development expenses climbed to $46.7 million from $42.5 million a year ago. Additionally, the number of downstream programs led by partners decreased to 40 from 44 at the end of the previous quarter. While the company announced positive interim Phase 1 clinical data for its ABCL635 candidate, investors focused on the challenging financial metrics.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103494780","isCrawlerRequest":true}